Xifaxan He denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for xifaxan he are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This as Not Medically Necessary

A medical-necessity denial for rifaximin (Xifaxan) for hepatic encephalopathy (HE) means Cigna determined that the clinical documentation submitted did not demonstrate that the drug meets their criteria for medically necessary care. This is the most common appeal type and also among the most frequently overturned. The denial rarely reflects a final clinical judgment — it typically reflects incomplete documentation at the time of the prior authorization request.

Cigna's medical-necessity criteria for rifaximin in HE are spelled out in their coverage policy. The most common gaps are: insufficient documentation of HE episode history, inadequate demonstration of prior treatments tried, or a prescriber letter that is too general to satisfy specific policy language.

## Why This Is Appealable

• Medical-necessity determinations are reviewable: Every federal framework — ACA §2719, ERISA §503, and state insurance law — gives you the right to challenge a medical-necessity denial with additional clinical evidence.
• ACA §2719 external review: After exhausting internal appeal levels, you can request independent external review. An external physician reviewer applies clinical standards, not just the insurer's internal policy. You generally have approximately four months from the denial notice; verify the exact deadline on your EOB.
• ERISA §503 full-and-fair review: Your employer plan must provide the specific criteria it used and must consider any new clinical information you submit.
• Expedited review: If delay would seriously jeopardize your health, request expedited processing at every level.

## Documentation to Gather

• Diagnosis confirmation: Physician records formally establishing your HE diagnosis, including any documented episodes, hospitalizations, cognitive or neurological assessments recorded in the chart, and the underlying liver disease history.
• Disease severity documentation: Any chart notes, specialist assessments, or imaging that conveys the severity and trajectory of your condition.
• Prior-treatment history with dates and outcomes: A chronological record of every HE-related treatment you have received — dates started, dates stopped, doses if already in the chart, and documented outcomes (response, side effects, failure).
• Prescriber medical-necessity letter: This is the most critical document. Ask your physician to write a letter that: (a) states your diagnosis and clinical severity, (b) lists prior treatments and their outcomes, (c) explains why rifaximin is medically necessary for you specifically, and (d) references the applicable hepatology society guideline organization.

## Criteria-Mapping Approach

Download Cigna's published coverage policy for rifaximin-HE from their website. Extract every criterion listed. Then construct a table: left column = the policy requirement; right column = the specific chart fact, date, or physician attestation that satisfies it. Submit this mapping with your appeal. Reviewers are far more likely to reverse a denial when the clinical record is presented as a direct answer to each policy element rather than as a narrative that may leave gaps.